ArticleZeitschrift fur Rheumatologie2026
[Osteoporosis in rheumatology-Diagnostics, risk assessment and modern treatment strategies].
Article in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory rheumatic diseases such as rheumatoid arthritis (RA) lead to local periarticular demineralization through localized arthritis in one or more joints; however, the autoimmune-mediated systemic inflammatory process is also a driver of systemic bone loss, osteoporosis, which leads to an increased risk of fractures. The Umbrella Organization Osteology (DVO) guidelines 2023 recommend a risk-adapted approach involving systematic fracture risk assessment, early baseline diagnostics and consistent specific osteoporosis treatment, including antiresorptive and osteoanabolic strategies. For rheumatology practice this means firmly integrating osteological assessment, including fracture risk management as well as pharmacological and nonpharmacological osteological treatment into the structured care of patients with inflammatory rheumatic diseases.
Indexed as
Identifiers
42867518What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.